氢原子百科 
人物经历
美国血液学会(ASH)、国际血栓与止血学会(ISTH)会员。国家自然科学基金心血管药理专业同行评议专家。于1990年、1993年和1998年分别从河南医科大学、中山医科大学分别获得医学学士、硕士和博士学位。
1993年7月 - 1995年8月在广州白云山制药总厂药物研究所从事抗生素的新药研发。1998年9月起在北京协和医院从事”纤溶酶原激活物抑制剂1 （PAI-1）多态性的研究”，2000年8月被评为“副研究员”。2000年8月起在在美国天普大学医学院Sol Sherry血栓研究中心从事血小板ADP受体的激活机制和以P2Y12受体为靶点的抗血小板药研究。2007年9月起在复旦大学上海医学院从事科研、教学工作。主要研究血小板激活的机制、抗血小板药作用机理和以P2Y12受体为靶点的抗血小板药的研发。与北京化工大学合作，首次报道了一种同时作用于血小板P2Y12受体和磷酸二酯酶、具有抗血小板活性的全新化合物BF0801。通过对BF0801进行结构改造，得到一种作用机制类似、活性更强的新化合物BF061，其抗血栓活性和氯吡格雷相似（小鼠肠系膜动脉FeCl3损伤血栓模型），但出血副作用更小。BF061的抗血栓作用同时被加拿大McMaster大学证实（小鼠提睾肌动脉激光损伤血栓模型）。在2011年7月在日本京都举行的“第23届国际血栓与止血学会大会” （International Society on Thrombosis and Haemostasis ⅩⅩⅢ Congress，ISTH 2011）上，该课题组抗血小板药的研究工作同时获得两项“青年研究学者奖”（Young Investigator Award)。承担国家自然科学基金（面上项目）5项、上海市科委“浦江计划”人才项目1项、科技部和上海市科委新药创制子课题各1项， 2008年首批首轮入选“上海高校特聘教授”(东方学者)。
代表论文
Hu L, Chang L, Zhang Y, Zhai L, Zhang S, Qi Z, Yan H, Yan Y, Luo X, Zhang S, Wang Y, Kunapuli SP, Ye H, Ding Z*.Platelets Express Activated P2Y12 Receptor in Patients with Diabetes. Circulation 2017; Epub ahead of print (doi: 10.1161/CIRCULATIONAHA.116.026995; IF: 19.3)
Jianqin Ye, Lili Zhai, Shenghui Zhang, Yan Zhang, Leilei Chen, Liang Hu, Si Zhang, Zhongren Ding*. Dl-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. Platelets 2015; 26(8): 736 - 44 ( IF: 3.2)
Si Zhang, Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei, Chen, Jozef S. Mruk, Guanjun Cheng, Satya P. Kunapuli, Zhongren Ding*. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and ThrombosisIs. Circulation 2015; 131(13): 1160 - 1170 (Featured work with an editorial; IF: 17.2)
Lei Liu, Jian Li, Yan Zhang, Shenghui Zhang, Jianqin Ye, Zhichao Wen, Jianping Ding, Satya P. Kunapuli, Xinping Luo*, Zhongren Ding*. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res 2014; 134(4): 866 - 76 (IF: 2.45)
SH Zhang, Y Zhang, J Shen, S Zhang, L Chen, J Gu, G Cheng, JS Mruk, L Zhu, SP Kunapuli, Z Ding*. Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase. J Thromb Haemost 2013; 11(10): 1855 - 1866 (IF: 5.6)
S Zhang, J Ye, Y Zhang, X Xu, J Liu, SH Zhang, SP Kunapuli, Z Ding*. P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation. J Thromb Haemost 2013; 11(1): 149 -160 (IF: 5.6)
Y Zhang, J Ye, L Hu, S Zhang, SH Zhang, Y Li, SP Kunapuli, Z Ding*. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12 receptor. J Thromb Haemost 2012; 10(10): 2149 - 2157 (IF: 6.1)
Pan C，Wei X*，Ye J，Liu G，Zhang S，Zhang Y，Du H，Ding Z*. BF066, a novel dual target antiplatelet agent without significant bleeding. PloS One 2012; 7: e40451 (IF: 3.7)
Guocheng Liu, Jiaxi Xu, Ning Chen, Si Zhang, Zhongren Ding, Hongguang Du. Synthesis of N6-alkyl(aryl)-2-alkyl(aryl)thioadenosines as antiplatelet agents. Eur J Med Chem 2012; 53: 114 - 123 (IF: 3.5)
Liang Hu, Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbin Wei, Xiaohui Zhang, Peter L. Gross, Satya P. Kunapuli, Zhongren Ding*. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106(6): 1203 - 14 (IF: 5.0)
Guocheng Liu, Jiaxi Xu, Ki Chul Park, Ning Chen, Si Zhang,Zhongren Ding, Feng Wang，Hongguang Du. Novel synthesis approach and antiplatelet-activity evaluation of 6-alkylamino-2,4-dialkyl(aryl)thiopyrimidines. Tetrahedron 2011; 67: 5156 - 5161 (IF: 3.0)
Zhang S, Hu L, Du H, Guo Y, Zhang Y, Niu H, Jin J, Zhang J, Liu J, Zhang X, Kunapuli SP,Ding Z*. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010; 104(4): 845 – 57 (cover figure; IF: 4.7)
Zhongren Ding, Yamini S. Bynagari, Sripal R. Mada, Joseph A Jakubowski, Satya P. Kunapuli. Involvement of extracellular cysteines and oligomeric structures in P2Y12 receptor antagonizing effects of clopidogrel and prasugrel. J Thromb Haemost 2009; 7(1): 232 – 4 (IF: 6.1)
Zhongren Ding, Soochong Kim, Satya P. Kunapuli. Identification of a potent P2Y12 receptor inverse agonist at constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 2006; 69(1): 338 - 345 (IF: 4.5)
Zhongren Ding, Florin Tuluc, Kavita R. Bandivadekan, Lili Zhang, Jianguo Jin, Satya P. Kunapuli. Arg333 and Arg334 in the C-terminus of the human P2Y1 receptor are crucial for Gq coupling. Am J Physiol 2005; 288(3): C559 - 67 (IF: 3.9)
Zhongren Ding*, Jia-Qi Pan. Distribution of PAI-1 promoter 4G/5G polymorphism in Chinese and functional characterization using a luciferase reporter vector. Ann Hematol 2005; 84(3): 183 - 187 (IF: 2.2)
Haripriya Shankar, Swaminathan Murugappan, Jianguo Jin, Soochong Kim，Zhongren Ding, Kevin Wickman, Satya P. Kunapuli. Role of G-protein gated inwardly-rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses. Blood 2004; 104(5):1335 - 43 (IF: 9.8)
John Meshki, Florin Tuluc, Ovidiu Bredetean, Zhongren Ding, Satya P. Kunapuli. Molecular mechanism of nucleotide-induced primary granule release in human neutrophils: role for the P2Y(2) receptor. Am J Physiol 2004; 286(2): C264 - 271 (IF: 3.9)
Satya P. Kunapuli, Zhongren Ding, Robert T. Dorsam, Soochong Kim, Swaminathan Murugappan, Todd M. Quiton. ADP receptors-Targets for developing antithrombotic agents. Curr Pharm Design 2003; 9(28): 2303 - 16 (IF: 5.5)
Zhongren Ding, Soochong Kim, Robert T. Dorsam, Jianguo Jin, Satya P. Kunapuli. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, C17 and C270. Blood 2003; 101(10): 3908 - 3914 (IF: 10.1)
1.
Ding Z
2.
Zhongren Ding
3.
Zhongren Ding
4.
Zhongren Ding
5.
Z Ding
6.
Z Ding*
7.
Z
8.
*
9.
Zhongren Ding,
10.
Zhongren Ding*
11.
Zhongren Ding
12.
Ding Z*
13.
Zhongren Ding
14.
Zhongren Ding
15.
Zhongren Ding
16.
Zhongren Ding*
17.
Zhongren Ding
18.
Zhongren Ding
19.
Zhongren Ding
20.
Zhongren Ding